Integra Lifesciences Holdings (IART) Cash from Operations (2009 - 2026)

Integra Lifesciences Holdings has disclosed Cash from Operations across 18 years of filings, most recently posting $22.8 million for Q2 2026.

• In Q2 2026, Cash from Operations rose 155.66% year-over-year to $22.8 million; the TTM figure through Jun 2026 stood at $85.3 million (up 20.37% YoY), while the FY2025 annual figure was $50.4 million, down 61.06% from the prior year.
• Cash from Operations came in at $22.8 million for Q2 2026 at Integra Lifesciences Holdings, up from $9.8 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $85.3 million in Q4 2022 to a low of -$11.3 million in Q1 2025.
• Average Cash from Operations over 5 years is $34.3 million, with a median of $27.5 million recorded in 2023.
• Year-over-year, Cash from Operations tumbled 171.45% in 2025 and surged 187.08% in 2026.
• Over 5 years, Cash from Operations stood at $85.3 million in 2022, then sank by 31.15% to $58.8 million in 2023, then dropped by 13.63% to $50.7 million in 2024, then tumbled by 76.71% to $11.8 million in 2025, then jumped by 92.98% to $22.8 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were $22.8 million in Q2 2026, $9.8 million in Q1 2026, and $11.8 million in Q4 2025.